Zai Lab's Q2 2025: Discrepancies in VYVGART Revenue, DLL3 Strategy, and Regulatory Timelines

VYVGART's impact on revenue and sales growth, DLL3 ADC development strategy, regulatory strategy and timeline for DLL3, NRDL listing timeline for bemarituzumab, and VYVGART revenue and growth expectations are the key contradictions discussed in Zai Lab Limited's latest 2025Q2 earnings call.



Revenue and Profitability Outlook:
- Zai Lab Limited reported total revenue grew 9% year-over-year to $110 million in the second quarter of 2025, driven by higher sales of VYVGART and new product launches.
- The company reaffirmed its full-year revenue guidance of USD 560 million to USD 590 million and expects to achieve profitability on an adjusted basis in the fourth quarter.
- Growth trends are supported by strong commercial execution and efficient spending, which have improved operating leverage.

VYVGART Performance and Pipeline:
- VYVGART's commercial performance saw record patient utilization, with a shift towards maintenance use and increasing patient duration.
- This was attributed to growing physician confidence and the July update to China's national MG guidelines, which elevated VYVGART's positioning.
- The company anticipates significant long-term potential for VYVGART, with ongoing submissions for regulatory approvals like the prefilled syringe and expansion into new indications.

Oncology Pipeline Advancements:
- Zoci/1310, a DLL3 ADC for small cell lung cancer, showed a 79% unconfirmed overall response rate and a 100% disease control rate at a median follow-up of 3.4 months.
- The trial's encouraging intracranial activity and well-tolerated safety profile led to the receipt of a Fast Track designation and plans for pivotal studies.
- These advancements are part of Zai Lab's strategy to develop globally competitive treatments, leveraging AI tools to optimize clinical trials.

Gastric Cancer Opportunity:
- The positive results from the FORTITUDE-101 study in gastric cancer support the potential for bemarituzumab as a significant treatment option.
- With over 450,000 patients and approximately 150,000 new cases annually, the gastric cancer market in China presents a substantial opportunity for Zai Lab.
- The company plans to leverage its existing sales force and infrastructure to capture this market, with regulatory submissions anticipated in the coming months.